| Literature DB >> 33354666 |
Afroditi Kapourani1, Vasiliki Valkanioti1, Konstantinos N Kontogiannopoulos1,2, Panagiotis Barmpalexis1.
Abstract
The objective of the present study was to evaluate the use of artificial neural networks (ANNs) in the development of a new chemometric model that will be able to simultaneously distinguish and quantify the percentage of the crystalline and the neat amorphous drug located within the drug-rich amorphous zones formed in an amorphous solid dispersion (ASD) system. Attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy was used, while Rivaroxaban (RIV, drug) and Soluplus® (SOL, matrix-carrier) were selected for the preparation of a suitable ASD model system. Adequate calibration and test sets were prepared by spiking different percentages of the crystalline and the amorphous drug in the ASDs (prepared by the melting - quench cooling approach), while a 24 full factorial experimental design was employed for the screening of ANN's structure and training parameters as well as spectra region selection and data preprocessing. Results showed increased prediction performance, measured based on the root mean squared error of prediction (RMSEp) for the test sample, for both the crystalline (RMSEp (crystal) = 0.86) and the amorphous (RMSEp (amorphous) = 2.14) drug. Comparison with traditional regression techniques, such as partial least square and principle component regressions, revealed the superiority of ANNs, indicating that in cases of high structural similarity between the investigated compounds (i.e., the crystalline and the amorphous forms of the same compound) the implementation of more powerful/sophisticated regression techniques, such as ANNs, is mandatory.Entities:
Keywords: ATR-FTIR spectroscopy; Amorphous solid dispersions; Artificial neural networks; Partial least square regression; Principle component analysis; Quantification method
Year: 2020 PMID: 33354666 PMCID: PMC7744708 DOI: 10.1016/j.ijpx.2020.100064
Source DB: PubMed Journal: Int J Pharm X ISSN: 2590-1567
Composition of samples used for the development and validation of the new analytical method.
| Code | RIV (% wt.) | ASD | |
|---|---|---|---|
| Crystalline | Amorphous | ||
| F1 | 0.25 | 0.75 | 99.00 |
| F2 | 0.50 | 0.50 | 99.00 |
| F3 | 2.25 | 0.75 | 97.00 |
| F4 | 1.50 | 1.50 | 97.00 |
| F5 | 1.25 | 3.75 | 95.00 |
| F6 | 2.50 | 2.50 | 95.00 |
| F7 | 5.25 | 1.75 | 93.00 |
| F8 | 3.50 | 3.50 | 93.00 |
| F9 | 2.00 | 6.00 | 92.00 |
| F10 | 4.00 | 4.00 | 92.00 |
| F11 | 7.50 | 2.50 | 90.00 |
| F12 | 5.00 | 5.00 | 90.00 |
| F13 | 3.75 | 11.25 | 85.00 |
| F14 | 7.50 | 7.50 | 85.00 |
| F15 | 15.00 | 5.00 | 80.00 |
| F16 | 10.00 | 10.00 | 80.00 |
| F17 | 7.50 | 22.50 | 70.00 |
| F18 | 15.00 | 15.00 | 70.00 |
| F19 | 30.00 | 10.00 | 60.00 |
| F20 | 20.00 | 20.00 | 60.00 |
| F21 | 12.50 | 37.50 | 50.00 |
| F22 | 25.00 | 25.00 | 50.00 |
| F23 | 45.00 | 15.00 | 40.00 |
| F24 | 30.00 | 30.00 | 40.00 |
| F25 | 17.50 | 52.50 | 30.00 |
| F26 | 35.00 | 35.00 | 30.00 |
| F27 | 60.00 | 20.00 | 20.00 |
| F28 | 40.00 | 40.00 | 20.00 |
| F29 | 22.50 | 67.50 | 10.00 |
| F30 | 45.00 | 45.00 | 10.00 |
ASD contained 20/80% wt. RIV/SOL
Test subset
Training subset
Experimental domain and RMSEp for the two-level full factorial design employed during ANN factor screening process.
| Hidden units (X1) | Iteration cycles (X2) | Spectra region [1/cm] (X3) | Transformation (X4) | RMSEp | |
|---|---|---|---|---|---|
| Crystalline | Amorphous | ||||
| 2 | 1000 | 800–1800 | Untreated | 1.22 ± 0.29 | 2.14 ± 0.57 |
| 2 | 5000 | 800–1800 | Untreated | 1.03 ± 0.01 | 2.81 ± 0.06 |
| 2 | 1000 | 2800–3500 | Untreated | 6.03 ± 0.45 | 3.32 ± 0.18 |
| 2 | 5000 | 2800–3500 | Untreated | 6.00 ± 0.02 | 3.74 ± 0.01 |
| 2 | 1000 | 800–1800 | 2nd derivative | 0.98 ± 0.04 | 2.80 ± 0.03 |
| 2 | 5000 | 800–1800 | 2nd derivative | 1.03 ± 0.01 | 2.74 ± 0.06 |
| 2 | 1000 | 2800–3500 | 2nd derivative | 7.09 ± 0.71 | 5.38 ± 0.28 |
| 2 | 5000 | 2800–3500 | 2nd derivative | 7.50 ± 0.10 | 5.44 ± 0.10 |
| 5 | 3000 | 800–1800 | Untreated | 6.74 ± 1.45 | 12.91 ± 1.52 |
| 5 | 3000 | 2800–3500 | Untreated | 5.63 ± 0.93 | 3.58 ± 0.27 |
| 5 | 3000 | 800–1800 | 2nd derivative | 0.86 ± 0.15 | 2.69 ± 0.07 |
| 5 | 3000 | 2800–3500 | 2nd derivative | 6.61 ± 0.87 | 6.94 ± 2.13 |
| 8 | 1000 | 800–1800 | Untreated | 3.00 ± 0.61 | 3.86 ± 0.07 |
| 8 | 5000 | 800–1800 | Untreated | 6.38 ± 0.14 | 11.41 ± 0.09 |
| 8 | 1000 | 2800–3500 | Untreated | 6.64 ± 0.73 | 3.93 ± 0.26 |
| 8 | 5000 | 2800–3500 | Untreated | 6.28 ± 1.72 | 4.05 ± 0.48 |
| 8 | 1000 | 800–1800 | 2nd derivative | 1.01 ± 0.06 | 2.80 ± 0.02 |
| 8 | 5000 | 800–1800 | 2nd derivative | 2.19 ± 0.72 | 4.28 ± 1.00 |
| 8 | 1000 | 2800–3500 | 2nd derivative | 7.00 ± 0.68 | 4.51 ± 0.99 |
| 8 | 5000 | 2800–3500 | 2nd derivative | 6.11 ± 0.72 | 6.83 ± 0.50 |
Fig. 1ATR − FTIR spectra of pure crystalline RIV (form I), amorphous RIV, SOL and RIV − SOL ASDs as received (a) and after 2nd derivative transformation (b).
Fig. 3Un-transformed (a) and 2nd derivate (b) ATR-FTIR spectra of samples containing the crystalline RIV, the amorphous RIV and the ASDs according to Table 1.
Fig. 2Score plots of the PCA of the un-transformed (a) and the second derivative transformed (b) ATR-FTIR spectra of the ASDs, the matrix/carrier (SOL) and the amorphous and crystalline form I RIV.
ANOVA results for the employed full factorial design (0.05 significance probability level).
| Factors | Crystalline | Amorphous | ||
|---|---|---|---|---|
| F-value | p-value | F-value | p-value | |
| X1 | 28.30 | < 0.0001 | 46.34 | < 0.0001 |
| X2 | 4.77 | 0.0342 | 31.36 | < 0.0001 |
| X3 | 429.41 | < 0.0001 | 37.39 | < 0.0001 |
| X4 | 8.40 | 0.0058 | 2.66 | 0.1097 |
| X1X2 | 4.53 | 0.0388 | 9.11 | 0.0042 |
| X1X3 | 34.34 | < 0.0001 | 30.49 | < 0.0001 |
| X1X4 | 20.91 | < 0.0001 | 19.87 | < 0.0001 |
| X2X3 | 8.91 | 0.0046 | 8.16 | 0.0064 |
| X2X4 | 0.26 | 0.6119 | 2.43 | 0.1260 |
| X3X4 | 27.40 | < 0.0001 | 30.91 | < 0.0001 |
significant factors
parental factors included into the MLR models
Fig. 4Two-way interaction effect plots based on the full-factorial experimental design employed for the determination of crystalline RIV within the ASD system.
Fig. 5Two-way interaction effect plots based on the full-factorial experimental design employed for the determination of amorphous RIV within the ASD system.
Fig. 6Optimal ANN architecture for the determination of the crystalline (a) and the amorphous (b) RIV content within the prepared RIV-SOL ASDs.
RMSEp for PCR and PLS regression fitting.
| RMSEp | ||||
|---|---|---|---|---|
| No-transformation | 2nd derivative | |||
| 800–1800 cm−1 | 2800–3500 cm−1 | 800–1800 cm−1 | 2800–3500 cm−1 | |
| PCR | ||||
| Crystalline | 9.60 | 7.42 | 9.94 | 11.41 |
| Amorphous | 10.12 | 15.83 | 13.45 | 17.96 |
| PLS | ||||
| Crystalline | 9.48 | 9.50 | 11.89 | 14.30 |
| Amorphous | 17.86 | 15.15 | 13.15 | 16.50 |